IGIM
SRPT icon

I.G. Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

I.G. Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$2.36M Hold
52,000
– – 0.01% 245
2017
Q2 		$1.75M Buy
52,000
+12,000
+30% +$391K 0.01% 276
2017
Q1 		$1.18M Hold
40,000
– – 0.01% 316
2016
Q4 		$1.1M Buy
+40,000
New +$1.61M 0.01% 320

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

I.G. Investment Management's SRPT Position: Q3 2017 in Review

I.G. Investment Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2017 at 52,000 shares worth $2.36M. The position accounts for 0.01% of the portfolio, ranked #245.

I.G. Investment Management first reported a position in SRPT in Q4 2016 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • I.G. Investment Management held 52,000 shares of Sarepta Therapeutics worth $2.36M as of Q3 2017.
  • I.G. Investment Management left its Sarepta Therapeutics share count unchanged in Q3 2017.
  • Sarepta Therapeutics made up 0.01% of I.G. Investment Management's portfolio in Q3 2017, its #245 holding.
  • I.G. Investment Management first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on I.G. Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.